Companies: 48,874 Total Market Cap: 132455990692658.24

Aspen Pharmacare Holdings Limited

JSE-APN

Healthcare Drug Manufacturers - Specialty & Generic

Rank #4699

Market Cap 2.90 B

Volume 1.31 M

Price 652.89

Change (%) 2.35%

Country or region

South Africa

Aspen Pharmacare Holdings Limited's latest marketcap:

2.90 B

As of 05/20/2025, Aspen Pharmacare Holdings Limited's market capitalization has reached $2.90 B. According to our data, Aspen Pharmacare Holdings Limited is the 4699th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.

Market Cap	2.90 B
Revenue (ttm)	2.49 B
Net Income (ttm)	245.39 M
Shares Out	444.21 M
EPS (ttm)	0.55
Forward PE	10.31
Ex-Dividend Date	09/18/2024
Earnings Date	09/03/2025

Market Cap Chart

Data Updated: 05/20/2025

Aspen Pharmacare Holdings Limited's yearly market capitalization.

Aspen Pharmacare Holdings Limited has seen its market value drop from R57.11 B to R52.92 B since 2020, representing a total decrease of 7.33% and an annual compound decline rate (CAGR) of 1.72%.

Date	Market Cap	Change (%)
05/20/2025	R52.92 B	-25.99%
12/31/2024	R73.23 B	-19.13%
12/29/2023	R90.55 B	49.27%
12/30/2022	R60.66 B	-40.62%
12/31/2021	R102.16 B	78.88%
12/31/2020	R57.11 B

Company Profile

About Aspen Pharmacare Holdings Limited

Aspen Pharmacare Holdings Limited, together with its subsidiaries, is a global manufacturer and supplier of specialty and branded pharmaceutical products. Headquartered in Durban, South Africa, the company was founded in 1850 and operates across two primary segments:

Commercial Pharmaceuticals
Manufacturing

Key Product Offerings

Aspen Pharmacare provides a diverse range of pharmaceutical solutions, including:

Anesthetics: Diprivan, Emla, Fraxiparine, Marcaine, Ultiva, and Xylocaine.
Therapeutic Solutions: Circadin (sleeping aid), Eltroxin (thyroid hormone), Foxair, Imuran (immunosuppressant), Maltofer (iron supplement), Mybulen (analgesic anti-inflammatory), and Ovestin (hormone replacement therapy).

Additional Operations

The company also engages in the manufacturing and sale of:

Active pharmaceutical ingredients (APIs).
Finished dose form products.

Frequently Asked Questions

As of 05/20/2025, Aspen Pharmacare Holdings Limited (including the parent company, if applicable) has an estimated market capitalization of $2.90 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.

Aspen Pharmacare Holdings Limited global market capitalization ranking is approximately 4699 as of 05/20/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.

Stock Detail

Country or region	South Africa
Founded	1850
IPO Date	n/a
Employees	9,350
CEO	Stephen Saad
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic
Address	Aspen Place Durban South Africa
Website	https://www.aspenpharma.com